Wells Fargo took its Emergent BioSolutions [EBS] rating to the equivalent of Equal-Weight from Overweight, in a research note dated 2021-01-08. Meanwhile, Chardan Capital Markets had maintained its rating on EBS to the earlier “Buy” rating, in a research note produced for clients July 31, 2020. In addition, Guggenheim launched coverage on September 12, 2019. The research firm rated EBS “a Buy”.
Is Emergent BioSolutions Inc. [NYSE:EBS] a Good Buy Right Now?
It should be noted that EBS technical indicators for short, intermediate as well as long term progress have placed an overall average of 40% as Buy. The average signal changed from 8% Sell in the last week and compares with 72% Sell in the past month. Data from Emergent BioSolutions Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 0.57 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.55 million shares while the medium term average advocated for 50% Sell. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.58 million shares.
EBS Price Performance
On Wall Street, Emergent BioSolutions Inc. [NYSE:EBS] finished Thursday’s session up 2.86% at $100.77. The stock went up to $102.10 at the same session while its lowest single day price was $97.78. In the last five days, it saw a rise of about 8.71%, Emergent BioSolutions Inc. shares gained by almost 12.47% since the beginning of the year. However, the share price has dropped to as low as -26.77% below its one year high. On 01/07/21, the company shares recorded $102.10, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $89.60. The company’s shares have inclined by 83.02% in the past year. The 50-day SMA achieved is $88.64 while the 200-day SMA is $90.66. Volume dropped to 0.4 million from 0.61 million in the previous session.
Emergent BioSolutions Inc. [EBS] Valuation Measures
Notably, Emergent BioSolutions Inc. [EBS] stock cannot be classified as a good candidate in the listing of underestimated low-priced Drug Manufacturers – Specialty & Generic companies to purchase soonest possible with the prevailing 12-month PE ratio of 32.40. The measure means the stock is exchanging at a premium as compared to the 24.75x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 4.15 PS value ratio is reported for the last one year of reported earnings. That is higher than the industry average of 2.92 which means EBS serve an unattractive investment opportunity compared to its competitors.
EBS Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 98.33 level, and in case of violation of this particular level, it will cause more drop to 95.90 level. On the upper level, 104.54 is still the key resistance. The stock may increase to the subsequent resistance at 102.65. The Relative Strength Index (RSI) pinned on the 14-day chart is 65.77, implying a neutral technical stance while the MACD stands at 4.06, meaning price will increase in the next trading period. Percent R indicator moved to 9.73%, implying bullish price movement. Stochastic %K at 88.83% suggest selling the stock.
What is the short interest in Emergent BioSolutions Inc.?
Short interest in the Emergent BioSolutions Inc. stock has plunged, decreasing by 100000.0 shares to total 2.07 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 1.97 million, data from Yahoo Finance shows. The increase of 4.83% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 5.45% of the overall float for the stock.
Emergent BioSolutions Inc.’s Biggest Shareholders: Who Owns Emergent BioSolutions Inc. [EBS]?
Filings by BlackRock Fund Advisors showed that the firm now holds a total of 4,498,560 shares or roughly 8.49% of the outstanding EBS shares. This means their shares have reduced by -1,761,634 from the 4,498,560 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, The Vanguard Group, Inc. updated stake is worth $350,944,779. Details in the latest 13F filings reveal that Neuberger Berman Investment Advis disposed off their -1.74% stake valued at $240,578,760 while SSgA Funds Management, Inc. cut theirs at $152,567,424. During the last quarter, Neuberger Berman Investment Advis liquidated -52,079 of its shares in Emergent BioSolutions Inc. while SSgA Funds Management, Inc. sold -360,542 shares. The EARNEST Partners LLC’s holdings currently number 1,394,794 shares at $140553391.38. According to the firm’s last 13F report, Dimensional Fund Advisors LP shares in the company at filing stood at 1,171,334 shares, roughly $95,967,395.
EBS Earnings Forecast For The Current Quarter
Emergent BioSolutions Inc. [EBS] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $556.69M and an earnings per share of $2.83 for Dec 2020. Looking further ahead, the company is expected to report revenue of $402.14M at an EPS of $1.84 for Mar 2021. The estimates represent upside of 25.00% and 26.37% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
EBS Earnings Estimates For The Current Year
For the financial year, Emergent BioSolutions Inc. [NYSE:EBS] is expected to bring in revenue of $1.53B. The returns are nearly $420.0 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 7.03, higher than that of FY19 by $4.12. Estimates put this year’s earnings growth at 141.60%, 26.30% for the next, and at an annual 9.20% over the next 5-year period. As for sales, forecasts are for an increase of 38.30% in the current fiscal year and a further 25.00% over the following year.